María Gestal-Mato

María Gestal-Mato

Auto-generated profile, based on publicly available information

María Gestal-Mato

Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2024 in Nature
Verified
Journal Article
Open access
PDF file
FSFrederike Sass
Frederike Sass
TMTao Ma
Tao Ma
JEJeppe H. Ekberg
Jeppe H. Ekberg
MKMelissa Kirigiti
Melissa Kirigiti
MUMario G. Ureña
Mario G. Ureña
ZGZachary Gerhart-Hines
Zachary Gerhart-Hines
The combination of decreasing food intake and increasing energy expenditure represents a powerful strategy for counteracting cardiometabolic diseases such as obesity and type 2 diabetes1. Yet current pharmacological approaches require conjugation of multiple receptor agonists to achieve both effects2,3,4, and so far, no safe energy-expending option has reached the clinic. Here we show that activation of neurokinin 2 receptor (NK2R) is sufficient to suppress appetite centrally and increase energy expenditure peripherally. We focused on NK2R after revealing its genetic links to obesity and glucose control. However, therapeutically exploiting NK2R signalling has previously been unattainable because its endogenous ligand, neurokinin A, is short-lived and lacks receptor specificity5,6. Therefore, we developed selective, long-acting NK2R agonists with potential for once-weekly administration in humans. In mice, these agonists elicit weight loss by inducing energy expenditure and non-aversive appetite suppression that circumvents canonical leptin signalling. Additionally, a hyperinsulinaemic–euglycaemic clamp reveals that NK2R agonism acutely enhances insulin sensitization. In diabetic, obese macaques, NK2R activation significantly decreases body weight, blood glucose, triglycerides and cholesterol, and ameliorates insulin resistance. These findings identify a single receptor target that leverages both energy-expending and appetite-suppressing programmes to improve energy homeostasis and reverse cardiometabolic dysfunction across species.

20 November 2024 in Nature
Verified
Journal Article
Closed access
PDF file
RRRaphael A. Reyes
Raphael A. Reyes
SRSai Sundar Rajan Raghavan
Sai Sundar Rajan Raghavan
NHNicholas Hurlburt
Nicholas Hurlburt
VIViola Introini
Viola Introini
SBSebastiaan Bol
Sebastiaan Bol
TLThomas Lavstsen
Thomas Lavstsen

8 September 2025 in bioRxiv
Verified
Preprint
Open access
VIViola Introini
Viola Introini
RLRory Km Long
Rory Km Long
OOOlawunmi R Oyerinde
Olawunmi R Oyerinde
MGMaría Gestal-Mato
María Gestal-Mato
LHLeticia Hartmann
Leticia Hartmann
MBMaria Bernabeu
Maria Bernabeu
Fever, a universal host defense in infection and inflammation, paradoxically contributes to neurological complications in malaria. While febrile temperatures enhance the expression of parasite virulence proteins that mediate vascular adhesion and disease severity, its effects in the endothelium remain elusive. Here we present a 3D fever-on-a-chip model that recapitulates human brain and lung microvessels under febrile conditions. Short febrile episodes at 40 °C, common in treated cerebral malaria patients, rapidly enhanced iRBC and immune cell binding under flow. Mechanistically, we demonstrated that this phenotype was driven by endothelial glycocalyx shedding, which exposed endothelial receptors EPCR and ICAM-1. Preserving glycocalyx integrity with a broad MMP inhibitor prevented the temperature-induced rise in cytoadhesion. These findings identify fever as a host-specific amplifier of vascular pathology in malaria and highlight endothelial-protective or antipyretic interventions as important strategies to mitigate febrile microvascular pathology.

25 June 2026 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
APArtem Pavlovskyi
Artem Pavlovskyi
YRYinhang Ren
Yinhang Ren
MGMaría Gestal-Mato
María Gestal-Mato
OOOle H. Olsen
Ole H. Olsen
TSThue W. Schwartz
Thue W. Schwartz
XLXiangyu Liu
Xiangyu Liu
Incretin-based obesity pharmacotherapies have revolutionized patient care but act predominantly by reducing food intake. Approaches that increase energy expenditure could improve efficacy but remain challenging to harness. Recently, neurokinin 2 receptor (NK2R) activation was shown to both lower food intake and stimulate energy expenditure in preclinical models. However, the endogenous NK2R ligand, NKA, crossreacts with other receptor family members that are linked to unwanted adverse effects. Therefore, understanding NK2R selectivity is the key to unlocking its therapeutic potential. Here we generated cryo-electron microscopy complexes of NK2R bound to NKA and several synthetic agonists to discover candidate interactions driving selectivity. Targeted receptor and ligand mutagenesis was then used to functionally validate the specific residues in the NK2R binding pocket and the C terminus of synthetic peptide agonists that were responsible for selectivity. These findings provide a structural framework for defining neurokinin selectivity and enable the development of improved NK2R agonists for clinical investigation.